Table 1.
Example of chemotherapy drugs application in combination with Fluorouracil in clinical trials.
| Study name | Intervention Model | Estimated Enrollment | Drugs | Phase | Date | NTC number | Major findings |
|---|---|---|---|---|---|---|---|
| 5FU/LV, Irinotecan, Temozolomide, and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. | Sequential Assignment | 18 | 1. Bevacizumab 2. Irinotecan 3. Leucovorin 4. 5-Fluorouracil 5. Temozolomide |
Phase 1 | 2020 | NCT04689347 | Recruiting |
| Metformin and 5-fluorouracil for Refractory Colorectal Cancer | Single Group Assignment | 50 | Metformin and Fluorouracil | Phase 2 | 2013 | NCT01941953 | 1. Metformin has anti-tumor activity (55). 2. Metformin decreases 5-FU side effects. |
| mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer (FIND) | Single Group Assignment | 18 | 1. Dalpiciclib 2. Oxaliplatin injection 3. Calcium folinate 4. 5-fluorouracil |
Phase 2 | 2022 | NCT05480280 | Recruiting |
| Study of Magrolimab Given Together With FOLFIRI/BEV in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | Parallel Assignment | 135 | 1. Magrolimab 2. Bevacizumab 3. Irinotecan 4. Fluorouracil 5. Leucovorin |
Phase 2 | 2022 | NCT05330429 | Recruiting |
| Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab | Parallel Assignment | 550 | 1. Irinotecan 2. Folinic Acid 3. 5-Fluorouracil 4. Cetuximab 5. Bevacizumab 6. Capecitabine 7. regorafenib 8. Irinotecan 125mg 9. Cetuximab wkly |
Phase 3 | 2016 | NCT02934529 | Recruiting |
| Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB | Parallel Assignment | 280 | 1. Bevacizumab 2. Cetuximab 3. 5-Fluorouracil 4. Irinotecan 5: Calcium levofolinate |
Phase 3 | 2021 | NCT04776655 | Recruiting |
| Systemic Chemotherapy Plus HAI(FUDR) vs Systemic Chemotherapy Alone For CRCLM | Parallel Assignment | 288 | 1. FUDR 2. Oxaliplatin 3. Leucovorin 4. 5-Fluorouracil |
Phase 3 | 2018 | NCT03500874 | Recruiting |
| A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer | Parallel Assignment | 84 | 1. Gemcitabine 2. Avastin 3. 5-FU/folinic acid 4. Oxaliplatin |
Phase 2 | 2009 | NCT00192075 | 1. Folinic acid, 5-fluorouracil, gemcitabine (FFG), and FOLFOX4 were generally well tolerated. 2. FGG has no potential advantage over 5-FU/folinic acid (56). |